IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Adamou et al.

Application Serial No.: To Be Assigned Art Unit: To Be Assigned

Filed: Concurrently Herewith Examiner: To Be Assigned

For: Calcitonin Gene Related Peptide Receptor Atty. Docket: PF129C2

Preliminary Amendment Under 37 C.F.R. § 1.115

Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to examination, Applicants respectfully request entry of the following amendments and remarks. Applicants submit herewith a Version With Markings Showing Changes Made. Please amend the application as follows.

In the Specification

On Page 1, please insert the following paragraph immediately after the title:

--This application is a continuation of U.S. Application Serial No. 09/455,442 filed December 6, 1999, which is a continuation of 08/461,250 filed June 5, 1995, which is a continuation-in-part of PCT/US95/01587, filed February 3, 1995, which is a continuation-in-part of PCT/US94/09235, filed August 16, 1994, to each of which benefit under 35 U.S.C. § 120 is claimed, and each of which is hereby incorporated by reference in its entirety.--

On Page 5, please delete the entire paragraph beginning on line 21, and replace with the following amended paragraph:

--Figure 1 shows the cDNA sequence (SEQ ID NO: 1) and the corresponding deduced amino acid sequence (SEQ ID NO: 2) of the CGRP receptor polypeptide of the present invention. The initial methionine amino acid is part of an 21 amino acid putative leader sequence that ends in a Threonine (Thr) residue. The standard one-letter abbreviations for amino acids are used. Two cryptic ATG codons (underlined) are present at amino acid positions -1 and -11 upstream from the putative authentic initiation codon.--

Docket No: PF129C2 1 Serial No: To Be Assigned

On Page 7, please delete the entire paragraph beginning on line 29, and replace with the following amended paragraph:

--Figure 10. Amino acid sequence comparison of CGRP receptor polypeptide (top line) to the human calcitonin receptor polypeptide (bottom line) (SEQ ID No: 8) illustrating 72 % similarity and 55 % identity at the amino acid level.--

On Page 7, the last partial paragraph bridging to Page 8, first partial paragraph, please delete the entire paragraph starting with "Figure 11", and replace with the following amended paragraph:

--Figure 11. Amino acid sequence comparison of CGRP receptor polypeptide (top line) to the rat calcitonin-like receptor (bottom line) (SEQ ID NO: 9) illustrating 91 identities at the amino acid level.--

Please replace the Sequence Listing with the substitute Sequence Listing (numbered pages 46-52) submitted herewith.

Remarks

The specification has been amended to add priority information. Sequence identifiers for SEQ ID NOS:1, 2, 8, and 9 have been added to the specification pursuant to 37 C.F.R. § 1.821(d) and replacement of the Sequence Listing with the substitute Sequence Listing last-filed in the parent application. The above-noted amendments are of a formal nature. No new matter has been introduced.

If there are any fees due in connection with the filing of this paper, please charge the fees to our deposit Account No. 08-3425. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Dated:	Jonathan L. Klein (Reg. No. 41,119)
	Attorney for Applicants
	Human Genome Sciences, Inc.

Human Genome Sciences, Inc 9410 Key West Avenue Rockville, MD 20850 Telephone: (301) 251-6015

JLK/DAS/mlm

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Adamou et al.

Application Serial No.: To Be Assigned Art Unit: To Be Assigned

Filed: Concurrently Herewith Examiner: To Be Assigned

For: Calcitonin Gene Related Peptide Receptor Atty. Docket: **PF129C2**

Version With Markings To Show Changes Made

The following new paragraph has been inserted on Page 1, immediately after the title:

This application is a continuation of U.S. Application Serial No. 09/455,442 filed December 6, 1999, which is a continuation of 08/461,250 filed June 5, 1995, which is a continuation-in-part of PCT/US95/01587, filed February 3, 1995, which is a continuation-in-part of PCT/US94/09235, filed August 16, 1994, to each of which benefit under 35 U.S.C. § 120 is claimed, and each of which are hereby incorporated by reference in their entirety.

On Page 5, the paragraph beginning in line 21, has been amended as follows:

Figure 1 shows the cDNA sequence (SEQ ID NO: 1) and the corresponding deduced amino acid sequence (SEQ ID NO: 2) of the CGRP receptor polypeptide of the present invention. The initial methionine amino acid is part of an 21 amino acid putative leader sequence that ends in a Threonine (Thr) residue. The standard one-letter abbreviations for amino acids are used. Two cryptic ATG codons (underlined) are present at amino acid positions -1 and -11 upstream from the putative authentic initiation codon.

On Page 7, the paragraph beginning on line 29, has been amended as follows:

Figure 10. Amino acid sequence comparison of CGRP receptor polypeptide (top line) to the human calcitonin receptor polypeptide (bottom line) (SEQ ID NO: 8) illustrating 72 % similarity and 55 % identity at the amino acid level.

On Page 7, the last partial paragraph bridging to Page 8, first partial paragraph, has been amended as follows:

Figure 11. Amino acid sequence comparison of CGRP receptor polypeptide (top line) to the rat calcitonin-like receptor (bottom line) (SEQ ID NO: 9) illustrating 91 [identity] identities at the amino acid level.